Elysium Therapeutics, Inc.

Elysium’s mission is to reduce suffering from acute pain, opioid-use disorder, and fatal opioid overdose by developing lifesaving, best-in-class products.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Akron, OH, USA
  • Currency USD
  • Founded May 2013
  • Employees 2
  • Incorporation Type C-corp
  • Website elysiumrx.com

Company Summary

Attractive risk/reward profile:
1. High-probability of Success: Proof-of-concept support its NCEs comprised of FDA-approved drugs
2. Capital Efficiency: Leverage non-dilutive grant funding ($16M)
3. Platform Opportunity: Diverse portfolio addresses key drivers of the opioid crisis; could yield multiple products within 5 years
4. Market: $B+ potential, with weak direct competition
5. IP: Strong with issued patents in the US and internationally

Team

  • A. Gregory Sturmer
    President and Chief Executive Officer

    Greg is a healthcare executive with over 25 years of strategic and operational experience. Before founding Elysium, Greg was CFO of Signature Therapeutics, where he raised over $60M. Previously, Greg was VP, Finance & Investor Relations at Theravance. Greg was responsible for strategic planning & investor relations from start-up through IPO. He was directly involved in negotiating two landmark deals with GSK that support its ~$4B valuation.

  • Thomas E Jenkins
    EVP and Chief Scientific Officer

    Tom has more than 20 years experience in the pharmaceutical industry. Before founding Elysium, Tom co-founded Theravance, Inc. then later Signature Therapeutics where he was CSO and primary inventor of all of their technologies and product candidates. Tom led a small, highly productive research team that advanced several compounds through hPOC and attracted $80M in financing. Tom is a recognized leader in opioid abuse-resistance technologies.

  • Greg Sturmer

Advisors

  • Wilson, Sonsini, Goodrich & Rosati
    Lawyer
    Unconfirmed

Previous Investors

  • Mid-Atlantic Bio Angels
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free